This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc. Nitric oxide breath analysis for the diagnosis of asthma. Lansdale: HAYES, Inc. Directory Publication. 2016
The measurement of nitric oxide (NO) concentration in expired breath has been introduced as an adjunct to or replacement for the established clinical and laboratory assessments for the diagnosis of asthma. Measurement of fractional exhaled nitric oxide (FENO) is a noninvasive diagnostic technique. The NO molecules exhaled in breath can be measured using a handheld electrochemical sensor or a large, stationary chemiluminescence gas analyzer.
Controversy: NO, which is normally produced by the respiratory tract mucosa, is believed to be a powerful mediator involved in airway inflammation. The level of FENO should serve as a surrogate indicator or marker
of airway inflammation, which can aggravate or be the primary cause of asthma. Asthma is a complex disease that has many potential contributing factors. Measurement of FENO may not be highly accurate for asthma diagnosis since it detects only 1 of these factors or FENO may only be accurate for diagnosis of a certain specific type of asthma such as eosinophilic or allergic asthma.
Relevant Questions: How accurate is exhaled NO breath testing for the diagnosis of asthma? Is FENO measurement safe? Which patients might be suitable candidates for diagnosis of asthma based on FENO?
Subject indexing assigned by CRD
Asthma; Breath Tests; Exhalation; Humans; Nitric Oxide
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published